TCT-89 Tradeoff between Myocardial Infarction and Bleeding in Relation to Bleeding Risk: insights from PARIS registry

Background Risk factors for bleeding overlap with those of thrombosis, thus complicating decision-making surrounding the duration or intensity of antiplatelet therapy especially in patients at high bleeding risk (HBR). In the high bleeding risk group patients were older with higher prevalence of fem...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2017-10, Vol.70 (18), p.B39-B39
Main Authors: Sorrentino, Sabato, Snyder, Clayton, Baber, Usman, Giustino, Gennaro, Sartori, Samantha, Farhan, Serdar, Vogel, Birgit, Chandrasekhar, Jaya, Ge, Zhen, Levine, Hannah, Cohen, David, Ariti, Cono, Gibson, C. Michael, Krucoff, Mitchell, Moliterno, David, Chieffo, Alaide, Henry, Timothy, Iakovou, Ioannis, Colombo, Antonio, Kini, Annapoorna, Witzenbichler, Bernhard, Steg, Philippe Gabriel, Pocock, Stuart, Mehran, Roxana
Format: Article
Language:English
Subjects:
Antiplatelet therapy
Bleeding
Cardiology
Cerebrovascular system
Heart attacks
Hemorrhage
Myocardial infarction
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Risk factors for bleeding overlap with those of thrombosis, thus complicating decision-making surrounding the duration or intensity of antiplatelet therapy especially in patients at high bleeding risk (HBR). In the high bleeding risk group patients were older with higher prevalence of female sex, hypertension, dyslipidemia, diabetes, prior coronary interventions and cerebrovascular events.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.09.145